JY 025 - Beijing Dongfang Biotech
Alternative Names: JY-025 - Beijing Dongfang BiotechLatest Information Update: 12 May 2021
At a glance
- Originator Beijing Dongfang Biotech
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer
Most Recent Events
- 12 May 2021 Preclinical trials in Non-small cell lung cancer in China (Parenteral)
- 12 May 2021 Beijing Dongfang Biotech plans a phase II/III trial for Non--small cell lung cancer (Combination therapy, First line therapy, Late stage disease, Metastatic disease) in July 2021 (NCT04874844)